Literature DB >> 19101575

Inhibition of vinyl carbamate-induced lung tumors and Kras2 mutations by the garlic derivative diallyl sulfone.

Lya G Hernandez1, Poh-Gek Forkert.   

Abstract

Vinyl carbamate (VC) is derived from ethyl carbamate (EC), a chemical found in alcoholic beverages and fermented foods. The objectives of this study were to characterize the formation of lung tumors induced by VC in F1 (Big BluexA/J) mice, and to identify the mutations formed in the Kras2 gene. In addition, we have tested the hypothesis that pretreatment with diallyl sulfone (DASO2) inhibits the adverse effects of VC. Mice were treated with VC (60 mg/kg, i.p.) or DASO2 (50 mg/kg, p.o.) 2 h prior to VC (DASO2/VC). Lung tumor multiplicity was significantly lower (21%) in mice treated with DASO2/VC than with VC. Lung tumors induced by VC are manifested as solid or papillary tumors, with the latter being regarded as a more malignant phenotype as they demonstrate no growth restrictions. Solid (42%) and papillary tumors (58%) were found in similar proportions in VC-treated mice. The number of papillary tumors was significantly decreased (44.5%) in mice treated with DASO2/VC, while there was a proportional increase (44.5%) in the number of solid tumors. The number of tumors with mutations in the first and second exon of Kras2 was significantly lower after treatment with DASO2/VC (7%) than after treatment with VC (61%). The mutations were mainly found in codon 61, and were identified as A-->T transversions (31%) and A-->G transitions (25%) in the second base, and A-->T transversions (12%) in the third base. All of these mutations were significantly reduced by DASO2 pretreatment. The number of tumors containing Kras2 mutations was highest (38%) in the large papillary tumors. Hence, mice treated with DASO2/VC had decreased frequencies of Kras2 mutations and reduced numbers of small and large papillary tumors, suggesting that activation of the Kras2 gene may be implicated in lung tumor formation and progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101575     DOI: 10.1016/j.mrfmmm.2008.11.013

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  5 in total

Review 1.  Unboxing the molecular modalities of mutagens in cancer.

Authors:  Smita Kumari; Sudhanshu Sharma; Dia Advani; Akanksha Khosla; Pravir Kumar; Rashmi K Ambasta
Journal:  Environ Sci Pollut Res Int       Date:  2021-10-05       Impact factor: 5.190

2.  Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice.

Authors:  Di Zhang; Jonathan Rennhack; Eran R Andrechek; Cheryl E Rockwell; Karen T Liby
Journal:  Antioxid Redox Signal       Date:  2018-04-16       Impact factor: 8.401

3.  The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.

Authors:  Jessica A Moerland; Di Zhang; Lyndsey A Reich; Sarah Carapellucci; Beth Lockwood; Ana S Leal; Teresa Krieger-Burke; Bilal Aleiwi; Edmund Ellsworth; Karen T Liby
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

4.  The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer.

Authors:  Lyndsey A Reich; Jessica A Moerland; Ana S Leal; Di Zhang; Sarah Carapellucci; Beth Lockwood; Peter W Jurutka; Pamela A Marshall; Carl E Wagner; Karen T Liby
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

5.  Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis.

Authors:  Alison K Bauer; Jennifer Fostel; Laura M Degraff; Elizabeth A Rondini; Christopher Walker; Sherry F Grissom; Julie Foley; Steven R Kleeberger
Journal:  Mol Cancer       Date:  2009-11-19       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.